Linifanib is an inhibitor of FMS-like tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor (VEGF) tyrosine kinases, and is involved in clinical trials concerning non-small cell lung cancer (NSCLC), breast, liver, and colorectal cancer as well as leukemia42–44. Here, FLT3 is linked to non-small cell lung carcinoma.